Mind Medicine (MindMed), a biotech company developing psychedelic-inspired therapies, announced it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD.

Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response. The study will be conducted by Kim Kuypers, PhD, of Maastricht University, a global authority on the use of low-dose psychedelics.

“Research into the practice of taking repeated low doses of psychedelics starts with the basics, looking at whether there is a time of day that influences the impact of these treatments,” Kuypers says in a press release. “We are investigating whether the repeated intake of lower doses could lead to realignment of patterns of thinking that would enable individuals to access levels of self-awareness that can provide an enriched experience of life.”

“Increasingly, claims are being made about so-called ‘microdosing’ of psychedelics regarding the potential to impact mental and physical well-being, cognition, memory, and specific aspects such as creativity and productivity,” Miri Halperin Wernli, PhD, MindMed’s executive president, says in a statement.

Photo: ID 156513536 © Bakalaerozz Photography | Dreamstime.com